SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study
Authors:
- Aino Latva-RaskuALAino Latva-Rasku
- Eleni RebelosEleni Rebelos
- Jouni TuiskuJTJouni Tuisku
- Richard AarnioRARichard Aarnio
- Achol BhowmikABAchol Bhowmik
- Sanna LaurilaSLSanna Laurila
- Minna Lahesmaa-HattingMLMinna Lahesmaa-Hatting
- Laura PekkarinenLPLaura Pekkarinen
- Henrik IsacksonHIHenrik Isackson
- Anna K. KirjavainenAKAnna K. Kirjavainen
- Jukka KoffertJKJukka Koffert
- 28 June 2024
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (9) , 1630-1637
Abstract
OBJECTIVE: The aim of this study was to investigate the impact of the sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on tissue fatty acid (FA) uptake in the skeletal muscle, brain, small intestine, and subcutaneous and visceral adipose tissue of individuals with type 2 diabetes by using positron emission tomography (PET). RESEARCH DESIGN AND METHODS: In a 6-week randomized double-blind placebo-controlled trial, 53 patients with type 2 diabetes treated with metformin received either 10 mg dapagliflozin or placebo daily. Tissue FA uptake was quantified at baseline and end of treatment with PET and the long-chain FA analog radiotracer 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid. Treatment effects were assessed using ANCOVA, and the results are reported as least square means and 95% CIs for the difference between groups. RESULTS: A total of 38 patients (dapagliflozin n = 21; placebo n = 17) completed the study. After 6 weeks, skeletal muscle FA uptake was increased by dapagliflozin compared with placebo (1.0 [0.07, 2.0] μmol ⋅ 100 g−1 ⋅ min−1; P = 0.032), whereas uptake was not significantly changed in the small intestine or visceral or subcutaneous adipose tissue. Dapagliflozin treatment significantly increased whole-brain FA uptake (0.10 [0.02, 0.17] μmol ⋅ 100 g−1 ⋅ min−1; P = 0.01), an effect observed in both gray and white matter regions. CONCLUSIONS: Six weeks of treatment with dapagliflozin increases skeletal muscle and brain FA uptake, partly driven by a rise in free FA availability. This finding is in accordance with previous indirect measurements showing enhanced FA metabolism in response to SGLT2 inhibition and extends the notion of a shift toward increased FA use to muscle and brain.Keywords
All Related Versions
Funding Information
- AstraZeneca Mölndal
- Suomen Lääketieteen Säätiö (6876)
This publication has 29 references indexed in Scilit:
- Carimas: An Extensive Medical Imaging Data Processing Tool for ResearchJournal of Digital Imaging, 2023
- Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trialMetabolism, 2022
- Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolismMolecular Metabolism, 2022
- Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitusNature Reviews Endocrinology, 2020
- Regional Brain Gray Matter Changes in Patients with Type 2 Diabetes MellitusScientific Reports, 2020
- Automated production of [18F]FTHA according to GMPJournal of Labelled Compounds and Radiopharmaceuticals, 2018
- Loss of Brain Aerobic Glycolysis in Normal Human AgingCell Metabolism, 2017
- Why does Brain Metabolism not Favor Burning of Fatty Acids to Provide Energy? - Reflections on Disadvantages of the Use of Free Fatty Acids as Fuel for BrainJournal of Cerebral Blood Flow & Metabolism, 2013
- Insulin in the brain: There and back againPharmacology & Therapeutics, 2012
- 14( R , S )-[ 18 F]Fluoro-6-thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardium and skeletal muscleEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002